COX-2 CV Risk Mechanism — FRCA Primary MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Cardiovascular risk due to inhibition of vascular prostacyclin without affecting platelet thromboxane
COX-2 inhibitors block vascular PGI2 (antithrombotic) production via COX-2 without affecting platelet TXA2 (prothrombotic) production via COX-1. This imbalance increases cardiovascular risk (MI / stroke). Rofecoxib was withdrawn for this reason.
Reference: Peck Hill Williams 2014 Pharmacology for Anaesthesia and Intensive Care